China approves vaccine trials for coronavirus, on par with US – Global Times

(GLOBAL TIMES) Leng Shumei, Chen Qingqing, Li Sikun, March 20, 2020

About 19 hours after the US announced it would start human trials for the first coronavirus vaccine, China revealed its own initial trials on the first vaccine the country developed, showing that the two largest economies are on par in the race to save the public health crisis. Given China’s system advantages, for example, in accelerating the examination and approval procedure, the country is expected to be ahead in putting the vaccine into the market, analysts said. Although the vaccine will likely not be available for wide use for another 12-18 months, it gave the world great hope in combating the disease.

After arriving at Wuhan, Chen Wei, a Chinese military major general, and her team launched pharmacy, pharmaceutical and toxicological research on COVID-19 vaccine in cooperation with local companies, based on their previous successful experiences in developing Ebola vaccine.

They quickly finished design, recombination, and production under the Good Manufacturing Practice and quality control review of the vaccine, according to CCTV.

The coronavirus vaccine developed by Chen’s team passed the registration review of clinical research and was approved for clinical trial on Monday night. 

She also noted that, consistent with international norms and domestic regulations, vaccines have been prepared for safe, effective, controllable quality and mass production.

On Tuesday, US media reported that the first dose of a COVID-19 vaccine developed in the country had begun clinical trials on Monday on 45 healthy volunteers, citing US health officials.

And local scientists estimated that the vaccine will likely not be available for wide use for another 12-18 months.  

Dozens of countries and regions have joined a “vaccine race” since the outbreak. Now as China and the US come to the same position in vaccine development, Chinese experts held that China would probably go one step ahead due to systematic advantages.